NCT01205243 - ZIAGEN® Post-marketing Surveillance | Biotech Hunter

Enrollment

671

Participants

Timeline

Start Date

November 1, 2010

Primary Completion Date

February 1, 2015

Study Completion Date

February 5, 2015

Conditions

Infection, Human Immunodeficiency Virus I

Interventions

DRUG

ZIAGEN®

Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Trial Locations (1)

400-711

GSK Investigational Site, Incheon